Immediate, ubiquitous and affordable image diagnosis combining the power of AI, smartphones and 3d printing to achieve Universal Diagnosis by 2030

ended

Early detection of both infectious diseases and chronic diseases plays a crucial role in all treatment and prevention strategies. Population ageing and healthcare budget pressures do not contribute to ease the pain under this scenario. Optic microscopy is still the gold standard for diagnosing several tens of pathologies. However, physicians have been using almost the same technology to detect diseases for the past 150 years, by manually reviewing samples under a microscope. This requires the time of an expert analyst at the right place and at the right moment as the sample is been taken, something not always available and affordable. SpotLab’s solution sits in the convergence of the physical and the digital world to reduce time, costs and distances of microscopy diagnosis. SpotLab is a diagnosis-as-a-service company based on three technological pillars: (1) a smartphone transformed into a portable, intelligent and low-cost medical device, manufactured with 3D printing and consumer electronics, (2) a flexible and easy to use telemedicine platform that can be tailored to multiple diagnosis protocols that is connected to the knowledge of worldwide physicians; and (3) a factory of AI models that prioritizes cases and assists diagnosis for multiple pathologies. After 5 years of research at the Universidad Politécnica de Madrid, SpotLab S.L. was founded in 2017. We are a multidisciplinary orchestra with a diverse team of 14 people, internationally awarded and recognized by our capacity of creating responsible innovation and products in the digital health space. SpotLab´s seed round allowed us to bring our product to TRL6. We need EU funding to complement our new investment round and industrialize our product (TRL6 to TLR9), obtain the relevant regulatory certifications (CE Mark); and validate its market disruption in dif SpotLab´s team motivation is to create a positive impact in the world. We prefer to provide 1 million diagnoses at €1 than 1 diagnosis at €1 million